文献速递药物不良反应与药物警戒

抗淀粉样蛋白单抗lecanemab治疗早期阿尔茨海默病的安全性与有效性:药物警戒视角

Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective.
PubMed 文献 · Br J Clin Pharmacol · 2025-03-06

本文为叙述性综述,讨论lecanemab在真实临床环境中监测安全性与有效性的需求。该药于2023年7月获美国FDA批准,2024年8月获英国MHRA批准,但英国NICE因治疗成本及疗效临床意义转化等问题未推荐其用于早期AD。文章还讨论了严重不良事件(包括ARIA)风险及风险最小化措施(RMMs)的评估需求。

要点

  • lecanemab已获US FDA、英国MHRA等多国批准用于早期AD。
  • 英国NICE因治疗成本及疗效临床意义转化问题未推荐lecanemab。
  • 临床试验数据显示包括ARIA在内的严重不良事件风险,需关注罕见危及生命事件。

核心结论

  • 需要在真实世界临床环境中建立稳健的方法监测lecanemab的安全性与有效性。
  • 应考虑医疗系统资源约束评估 proposed 风险最小化措施(RMMs)。

研究设计与样本

  • 叙述性综述,讨论lecanemab获批后的药物警戒监测需求与风险最小化措施评估。

主要发现

  • 英国NICE因治疗成本及疗效结局向临床有意义改善的转化等问题未推荐lecanemab用于早期AD。
  • 临床试验数据显示包括ARIA在内的严重不良事件风险,存在罕见危及生命事件的担忧。

临床怎么用

  • 在真实临床环境中需建立稳健方法监测lecanemab的安全性与有效性。
  • 需结合医疗系统资源约束评估风险最小化措施(RMMs)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of humanized IgG1 anti-amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease-modifying effects for patients with early Alzheimer's disease (AD). Lecanemab, which gained marketing approval by the United States Food and Drug Administration (US FDA) in July 2023, has since been approved in multiple countries, including the United Kingdom (UK). The decision by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to approve lecanemab in August 2024 followed similar regulatory decisions in the US and Japan. However, at the time of approval, the decision contrasted with that of the European Medicine Agency (EMA) in July 2024. Subsequently, the EMA recommended the marketing approval of lecanemab in November 2024 following a re-examination of further data submitted by the Marketing Authorisation Holder. The UK's National Institute for Health and Care Excellence (NICE) has not recommended lecanemab for use in early AD amid concerns, including treatment cost and the translation of efficacy outcomes into clinically meaningful improvement. The risks of serious adverse events (SAEs), including amyloid-related imaging abnormalities (ARIA), have also emerged from clinical trial data with a concern for the potential for rare, life-threatening events. This narrative review discusses the requirement for a robust method of monitoring the safety and effectiveness of lecanemab in the real-world clinical setting considering recent regulatory decisions. Additionally, the need to evaluate proposed risk minimization measures (RMMs) is discussed considering the resource constraints of healthcare systems, such as those faced by the UK's National Health Service (NHS).

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Bobbins A, Davies M, Lynn E, et al. Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective. Br J Clin Pharmacol. 2025. PMID: 40051090. doi:10.1002/bcp.70021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。